Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Crispr

Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Investors Business Daily

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

MarketBeat

Stock Market Today: Dow Jones Up As Elon Musk SpaceX Play Rockets; Cathie Wood Loads Up On This Stock Amid 43% Dive (Live Coverage)

The Dow Jones rose on the stock market today even as Nvidia fell. Tesla stock rose while Cathie Wood bought a plunging stock. Bitcoin popped.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Pfizer stock closed flat Thursday after the company pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Investors Business Daily

3 Cathie Wood Stocks Analysts Like Better Than Tesla

While Ark Invest scoops up Tesla, these three Cathie Wood picks have higher analyst ratings than the struggling EV leader.

Barchart

Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why

Crispr stock is down for the fifth straight week as the top Cathie Wood's holding struggles amid dim expectations for its gene-editing drug.

Investors Business Daily

Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug

Beam stock launched a year-high Tuesday as enthusiasm grows for its next-generation form of gene editing, a rival to CRISPR.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Crispr Stock Whipsaws As Wall Street Watches Its Gene-Editing Blockbuster Candidate

Crispr Therapeutics reported its first profit in 10 quarters on Wednesday, but CRSP stock whipsawed.

Investors Business Daily

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

Investors Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.

Investors Business Daily

Crispr Stock Whipsaws Lower After FDA Approves Gene-Editing Treatment

Crispr stock crashed after FDA approved a groundbreaking gene-editing treatment. CRSP stock was last off around 11%.

Investors Business Daily

Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug

In a world first, regulators in the UK approved Crispr's gene-editing treatment for two blood diseases on Thursday, and CRSP stock surged.

Investors Business Daily

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

Investors Business Daily

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug

The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

LiveScience

1st gene-edited snakes use mysterious 'Turing patterns' to achieve near-perfect hexagonal scales

Scientists used CRISPR editing to make the world's 1st genetically modified snakes, giving new insight into how the reptiles develop their patterned scales

Investors Business Daily

Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months

The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday.

Investors Business Daily

Dow Jones Futures Rise: S&P 500 Nears Key Support As Nvidia Earnings Loom; Here's What To Do Now

The Nasdaq and S&P 500 have tumbled to just above critical support as Treasury yields spike. Nvidia earnings are on tap.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Genetics, Alzheimer's And AI — Why 2023 Could Be The Year For Biotech Stocks

If there's one biotech area to watch in 2023, it's genetic medicine, like CRISPR. But other trends also point to a big year for biotech stocks.

Investors Business Daily

Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug

Crispr said Tuesday it will begin asking the FDA to approve its gene-editing blood diseases treatment in November, and CRSP stock jumped.

Investors Business Daily

Dow Jones Futures Await Jobs Report; Market Rallies To Big Trouble Area

The major indexes rallied Thursday right to where they've struggled this year. Here are 5 stocks triggering buy signals.

Investors Business Daily

Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?

Crispr Therapeutics could have a "functional cure" for two inherited blood diseases, analysts said Monday, but CRSP stock plummeted.

Investors Business Daily

How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing

GBT said Friday its sickle cell treatment, Oxbryta, helped lower markers of the disorder in a real-world study, but GBT stock yo-yoed.

Investors Business Daily

Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis

Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.